Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, PHARMA-BIO SERV, INC. reported revenue of $9M, down 5.3% year over year. Operating margin was -7.1% and net margin -1.1%, on a free-cash-flow margin of -2.5% with capital expenditure at 0.1% of revenue. Every figure is computed directly from PBSV's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $9M | -7.1% | -1.1% |
| FY2024 | $10M | -13.5% | -8.2% |
| FY2023 | $17M | 6.6% | 7.7% |
| FY2022 | $19M | 6.1% | 5.2% |
| FY2021 | $20M | -19.2% | -10.4% |
How does PBSV compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: AACG · ABSI · ACCS · ACHC · ACM · ADUS
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.